NANOG and breast cancer: Western blotting analysis revealed that the upregulation of Nanog, OCT4, and SOX2 was observed in breast cancer cells that exhibited overexpression of SNORA47, whereas a downregulation of these markers was evident in cells treated with ASOs targeting SNORA47 (Fig. 2A-D).